

# QUARTERLY INVESTMENT REVIEW

## Equity Dislocation Investment Fund USD Class A

### RETURNS (%) (LOCAL)

	Cumulative (%)		Annualized (%)				
	QTD	YTD	1 Year	3 Years	5 Years	10 Years	ITD
Net of Fees Fund (USD Class A)	-1.62	2.34	2.34	–	–	–	3.48
Gross of Fees Fund (USD Class A)	-1.08	4.58	4.58	–	–	–	5.82
FTSE 3-Mo. T-Bill	1.41	5.26	5.26	–	–	–	2.54
Value Added (vs. FTSE 3-Mo. T-Bill)	-3.02	-2.92	-2.92	–	–	–	0.93

### Major Performance Drivers

For the fourth quarter of 2023, MSCI ACWI returned 11.0%, with MSCI ACWI Value underperforming with a return of 9.2% and MSCI ACWI Growth outperforming with a return of 12.7%. The Equity Dislocation Investment Fund aims to be dollar and (broadly) beta neutral and, for the quarter, it had an average long exposure of 101% and an average short exposure of 101%. The long portfolio outperformed MSCI ACWI Value, but the short book detracted alpha as it had better performance than ACWI Growth. The fourth quarter net return for the Equity Dislocation Investment Fund is ahead of MSCI ACWI Value's -3.5% performance versus MSCI ACWI Growth for the quarter. Since inception, the portfolio is well ahead of ACWI Value minus ACWI Growth, and we are very pleased by the strong return profile. We believe that the opportunity set remains extremely compelling, and the strong rebound by Growth in 2023 offers an attractive entry point to the portfolio.

For the quarter, stock selection within countries across the long book added +150 bps relative to MSCI ACWI, driven by the U.S. (+110 bps), with no significant detractors. Stock selection in the short book had a total impact against MSCI ACWI of -340 bps. The biggest detractors were the U.S. (-210 bps), the UK (-60 bps), and Japan (-40 bps), while the biggest contributor was Korea (+30 bps). There were some modest country bets, although these are typically residuals driven by bottom-up security selection, and they had an aggregate -10 bps impact on performance for the fourth quarter.

We are prepared to run modestly larger sector bets, up to about 10% net long or short, and the two biggest positions in this regard over the quarter were a 5.1% net long position in Financials and a 4.1% net short position in Industrials. Our sector positioning detracted -30 bps from performance. Stock selection across the long book was positive in four of the eleven sectors and broadly flat in the other seven sectors, adding +240 bps altogether. The biggest contributors were Financials (+90 bps), Consumer Discretionary (+60 bps), and Energy (+50bps). Stock selection in the short book was negative in seven of the eleven sectors, broadly flat in three sectors and positive in the other one, with a total impact of -410 bps detracted from performance in aggregate. The biggest negative impacts came from Health Care (-80 bps), Information Technology (-80 bps), Financials (-70 bps), and Communication Services (-70 bps), while the sole contributor was Industrials (+20 bps).

Given the market's rebound, it was perhaps unsurprising that all of the top five biggest contributors at the total portfolio level were long positions. These included Expedia (U.S. Consumer Discretionary), Intel (U.S. Information Technology), Capital One (U.S. Financials), Builders FirstSource (U.S. Industrials), and Qualcomm (U.S. Information Technology). No long positions featured in the top five biggest detractors at the total portfolio level.

Inception Date: 10-May-21

This is a marketing communication. This is not a contractually binding document. Please refer to the prospectus and to the KIID/PRIIPS KID and do not base any final investment decision on this communication alone. **Risks:** Risks associated with investing in the Fund may include Equities Risks, Short Investment Exposure Risks, Risks of Non-U.S. Investments, Preferred Securities Risk and Depositary Receipts Risk. For a more complete discussion of these risks and others, please consult the Fund's Prospectus. Returns shown for periods greater than one year are on an annualized basis. To obtain performance information to the most recent month-end, visit [www.gmo.com](http://www.gmo.com).

Net of all fees and expenses after reimbursement by the Manager, but not transaction costs, if any. If certain expenses were not reimbursed, performance would be lower.

**Performance data quoted represents past performance and is not indicative of future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance data may be lower or higher than the performance data provided herein.** The portfolio is not managed relative to a benchmark. References to an index are for informational purposes only.

# QUARTERLY INVESTMENT REVIEW

## PRODUCT OVERVIEW

The GMO Equity Dislocation Investment Fund seeks high total return. It aims to own attractively valued equities while correspondingly shorting equities where we believe that valuations are reflective of implausible growth expectations. Currently, the Fund is long global Value, short global Growth, to take advantage of the exceptionally wide valuation spread between Value and Growth.

The eligible universe for both the long and short side spans the market capitalization spectrum and includes both developed and emerging markets. Utilizing GMO's proprietary Price to Fair Value model to actively select the cheapest and most expensive stocks, the portfolio is diversified across sectors, countries, and regions and is intended to be approximately beta neutral.

## IMPORTANT INFORMATION

**Comparator Index(es):** The FTSE 3-Month Treasury Bill Index is an independently maintained and widely published index comprised of short-term U.S. Treasury bills.

**An investor should consider the fund's investment objectives, risks, charges and expenses before investing. This and other important information can be found in the funds prospectus. To obtain a prospectus please visit [www.gmo.com](http://www.gmo.com). Read the prospectus carefully before investing.**

GMO UK Limited Authorised and Regulated by the Financial Conduct Authority Registered no 4658801 England. GMO Netherlands is registered with the AFM.

The above Fund has not been registered under the United States Investment Company Act of 1940, as amended, nor the U.S. Securities Act of 1933, as amended. None of the shares may be offered or sold, directly or indirectly, in the U.S. or to any U.S. Person, unless the securities are registered under the Act or an exemption from the registration requirements of the Act is available. A U.S. Person is defined as (a) any individual who is a citizen or resident of the U.S. for federal income tax purposes; (b) a corporation, partnership, or other entity created or organized under the laws of or existing in the U.S.; (c) an estate or trust the income of which is subject to U.S. federal income tax regardless of whether such income is effectively connected with a U.S. trade or business.

This is a marketing communication. This is not a contractually binding document. Please refer to the prospectus and to the KIID/PRIIPS KID and do not base any final investment decision on this communication alone.

Investors and potential investors can also obtain the prospectus and key investor information, in English and other languages, and a summary of investor rights and information on access to collective redress mechanisms at the following website: <https://www.gmo.com/europe/product-index-page/alternatives/equity-dislocation-strategy/equity-dislocation-investment-fund/>

Please note that GMO Investments ICAV and GMO Funds PLC may decide to terminate the arrangements made for the marketing of the sub-funds in one or more EU member states pursuant to the UCITS marketing passport in accordance with the procedure provided for under the applicable laws that implement Article 93a of Directive 2009/65/EC (the UCITS Directive).

A full list of fees and charges applied to investment can be found in the prospectus and in the KIID/PRIIPS KID, available at: <https://www.gmo.com/europe/product-index-page/alternatives/equity-dislocation-strategy/equity-dislocation-investment-fund/>

This advertisement has not been reviewed by the Monetary Authority of Singapore.

## ABOUT GMO

Founded in 1977, GMO is a global asset manager committed to delivering superior performance and advice to our clients. We are privately owned, which allows us to singularly focus on our sole business – achieving outstanding long-term client investment outcomes. Offering multi-asset, equity, fixed income, and alternative strategies, we invest with a long-term, valuation-based philosophical approach.

AMSTERDAM

BOSTON

LONDON

SAN FRANCISCO

SINGAPORE

SYDNEY

TOKYO\*

\*Representative Office

[www.GMO.com](http://www.GMO.com)